The More Life Company Corp. (the “Company” or “MLCO”), (CSE: MLCO) (OTC: TMLCF) is pleased to announce that it has entered into a strategic letter of intent (“LOI”) with an established U.S. 503A compounding pharmacy to advance the development, compounding and commercialization of Quicksome™-enabled prescription compounded pharmaceutical products in the United States.

The contemplated relationship is designed to establish dedicated U.S. compounding capability for Quicksome, combining MLCO’s proprietary formulation and delivery technology with an experienced U.S. partner’s compounding, formulation development, pharmacy, dispensing, national fulfillment and telemedicine capabilities.

Initial opportunities are being evaluated across hormone replacement, peptides and other active compounds, with the potential to support an expanding portfolio of Quicksome-enabled products across multiple therapeutic and wellness categories.

The parties to the LOI have mutually agreed not to publicly identify the U.S. partner at this stage as they focus on operational readiness, compounding implementation planning, initial business development and completion of definitive documentation.

KEY TERMS

  • Proposed Relationship: The parties intend to evaluate the development, compounding and commercialization of mutually approved Quicksome™-enabled prescription compounded pharmaceutical products in the United States.

  • Commercial Framework: The proposed relationship would include a Quicksome™ technology licensing model and potential exclusivity within the defined U.S. prescription-compounding field, with the specific terms to be set out in definitive documentation.

  • Next Steps: The parties will conduct due diligence, evaluate implementation requirements and work toward definitive documentation. Except for certain customary provisions, the LOI is non-binding.

KEY PROPOSED RELATIONSHIP HIGHLIGHTS

  • U.S. Compounding Capability: Advancing a dedicated U.S. pathway for the development, compounding and commercialization of Quicksome-enabled prescription compounded pharmaceutical products.

  • Operational Readiness: Advancing the equipment, facility, environmental-control and implementation work required to establish dedicated Quicksome compounding capability within the partner’s existing U.S. pharmacy infrastructure.

  • Expanding Product Portfolio: Initially evaluating hormone replacement, peptides and other active compounds where Quicksome may provide meaningful formulation, delivery, patient-experience or commercial advantages.

  • National Commercial Reach: Leveraging an established U.S. pharmacy platform with national dispensing and fulfillment capabilities and existing relationships across healthcare and telemedicine channels.

  • Business Development: Beginning selected discussions with prospective customers and commercial partners while operational readiness and definitive documentation advance.

BUILDING ON RECENT QUICKSOME™ TESTOSTERONE RESULTS

The LOI follows MLCO’s recently announced results from a third-party administered human pharmacokinetic study evaluating United States Pharmacopeia (“USP”) grade testosterone formulated using the Company’s Quicksome™ sublingual delivery technology.

Management views the study as having provided an important new human validation point for the Quicksome platform and supports the Company’s continued work toward differentiated approaches to hormone delivery.

MLCO believes the commercial opportunity extends across hormones, peptides and other active compounds, while MLCO’s broader Quicksome development work includes applications such as CoQ10 and other molecules where improved delivery, stability, dose efficiency or user experience may create commercial value.

“Our work with Quicksome has increasingly pointed us toward a much larger opportunity in compounded pharmaceuticals. Developing differentiated formulations is only part of that opportunity. We also need the compounding, pharmacy, dispensing and fulfillment infrastructure capable of bringing those products into the market,” stated Dennis Hancock, President and Chief Executive Officer of The More Life Company.

“What excites us is that we are not building around a single molecule or therapeutic category. Testosterone provides an important recent human validation point, while the broader opportunity may extend across hormones, peptides and other active compounds where Quicksome may create meaningful differentiation.”

“We are now bringing the technology, U.S. compounding infrastructure and commercial channels together, and we believe that creates a significant new business-development opportunity for The More Life Company.”

QUICKSOME™ BUSINESS DEVELOPMENT EXPANDING

With this U.S. commercialization pathway advancing, MLCO is expanding discussions with telemedicine platforms, healthcare organizations, pharmaceutical developers and other commercial partners interested in evaluating Quicksome-enabled applications.

MLCO and its prospective U.S. partner plan to concurrently advance definitive documentation, operational readiness, detailed equipment and facility requirements, initial product prioritization and selected commercial discussions.

ABOUT QUICKSOME™

Quicksome™ is The More Life Company’s patented desiccated liposomal formulation and delivery technology. The platform utilizes proprietary formulation approaches and stabilizing molecules to encapsulate and formulate active ingredients into efficient dosage formats designed to support rapid delivery, precision dosing and improved formulation performance.

The Company is advancing Quicksome across human health applications where formulation, stability, bioavailability, dose efficiency, convenience and needle-free delivery represent potential opportunities for innovation.

ABOUT THE MORE LIFE COMPANY CORP.

The More Life Company Corp., formerly Mountain Valley MD Holdings Inc., is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:

• patented Quicksome™ oral formulation and delivery technologies;

• patented Quicksol™ solubility formulation technology; and

• licensed product reseller of Agrarius™, a novel agricultural plant signaling technology.

Consistent with its vision towards “More Life”, the Company applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, the Company’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

The Company’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.

The Company’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

The Company’s licensed Agrarius™ agricultural plant signaling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

For more Company information and contact details, visit www.themorelife.company.

themorelife.company

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this news release may constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information is often, but not always, identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intend”, “may”, “plan”, “potential”, “should”, “will” and similar expressions, or statements that events, conditions or results “can”, “could”, “may”, “should” or “will” occur or be achieved.

Forward-looking information contained in this news release includes, but is not limited to, statements regarding the negotiation and execution of definitive documentation with the U.S. compounding pharmacy; the establishment and operational readiness of dedicated Quicksome compounding capability in the United States; equipment, facility, environmental-control and implementation requirements; the timing and outcome of any on-site facility readiness; the development of a Quicksome technology licensing model; the evaluation, prioritization, development, compounding and commercialization of hormone replacement, peptide, CoQ10 and other Quicksome-enabled applications; the expansion of business-development discussions with prospective customers and commercial partners; and the potential commercial value, differentiation and market opportunities associated with Quicksome-enabled products.

Forward-looking information is based on management’s current expectations, assumptions and beliefs as of the date of this news release and is subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or developments to differ materially from those expressed or implied by such forward-looking information. These factors include, among others, the ability of the parties to negotiate and execute definitive documentation; the outcome of facility, equipment and operational-readiness assessments; regulatory, pharmacy, compounding and other requirements applicable to contemplated products and activities; the results of future formulation, validation and development work; customer and market acceptance; the availability of capital, commercial partners and other resources; and other risks associated with the development and commercialization of pharmaceutical, nutraceutical and delivery technologies.

There can be no assurance that definitive documentation will be executed, that the contemplated U.S. compounding capability will be established on the timing or terms currently anticipated, that any particular Quicksome-enabled formulation will be developed or commercialized, that prospective business-development discussions will result in commercial arrangements, or that any Quicksome™ formulation will receive applicable regulatory authorization or achieve commercial adoption.

Readers are cautioned not to place undue reliance on forward-looking information. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Neither the CSE nor OTC Markets Group has reviewed or approved the contents of this press release.

Media gallery

About The Author
Business Wire